Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences (ACHV)
:ACHV
ACHV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.51 - $5.59
Previous CloseN/A
Volume131.37K
Average Volume (3M)189.32K
Market Cap
$99.20M
Enterprise Value$97.08M
Total Cash (Recent Filing)$66.40M
Total Debt (Recent Filing)$17.19M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 08, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding34,685,074
10 Day Avg. Volume181,394
30 Day Avg. Volume189,321
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$13.00Price Target Upside354.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Achieve Life Sciences News
PremiumCompany Announcements
Achieve Life Sciences: Cautious Optimism in Earnings Call
PremiumCompany Announcements
Achieve Life Sciences Reports 2024 Financial Results
PremiumCompany Announcements
Achieve Life Sciences Announces Board of Directors Changes---
Bulls Say, Bears Say
Bulls Say
Financial OutlookACHV ended 3Q24 with a cash position of $42.9 million, which the company estimates will be sufficient to fund operations into 2H25.
Market StrategyThe planned digital-forward, partnered commercial strategy is focused on reaching high decile primary care physicians and one-quarter of the smoking population that is actively seeking to quit.
Regulatory ProgressFollowing a positive End-of-Phase II meeting with the FDA, ACHV is planning to start the Phase III ORCA-V2.
Bears Say
Study DelaysThe Company announced it intends to delay the initiation of its financing-dependent Phase 3 registrational study in vaping cessation to 1H26 from 3Q25.
---
Ownership Overview
10.47% Insiders
13.76% Mutual Funds
15.93% Other Institutional Investors
50.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.51 and its highest was $5.59 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $99.20M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on Mar 11, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.341 by -$0.019.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.38.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 34,685,074 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.341. Following the earnings report the stock price went down -4.575%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (354.55% Upside)
$13.00 (354.55% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $57.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.75%
12-Months-Change
Fundamentals
Return on Equity
-409.51%
Trailing 12-Months
Asset Growth
99.44%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
---
ACHV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company on the cusp of significant milestones with the upcoming NDA submission for cytisinicline, highlighting strong progress in clinical trials and financial health. However, challenges remain, particularly in securing financing for future vaping cessation trials and managing high operating expenses. The overall sentiment is cautiously optimistic, with substantial achievements in place but significant dependencies on future regulatory approvals.Read More>---
ACHV Stock 12 Month Forecast
Average Price Target
$13.00
▲(354.55% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-1.55%
reiterated a buy rating 3 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -1.55% per trade.
---